US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...

AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year. Prior to the deal closing, Cerevel had reported a successful Phase 3 study of tavapadon as ...

AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...

AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary ...

Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the ...

AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...